Content about Atrial fibrillation

January 2, 2013
FDA approves Bristol-Myers Squibb's Eliquis to reduce risk of stroke, blood clots

The Food and Drug Administration last week approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. Eliquis is manufactured by Bristol-Myers Squibb, and marketed by BMS and Pfizer.

May 24, 2012
FDA panel declines to recommend new approval for J&J anticlotting drug

A Food and Drug Administration expert panel has recommended against expanding the approval of a Johnson & Johnson drug, the company said.

May 3, 2012
J&J seeks additional approval for anti-clotting drug

Drug maker Johnson & Johnson is seeking approval from the Food and Drug Administration for a drug to treat patients with deep vein thrombosis or pulmonary embolism, the company said.

November 29, 2011
FDA accepts Eliquis for review

A drug designed to prevent stroke and systemic embolism in patients with atrial fibrillation has been accepted for review by the Food and Drug Administration.

November 7, 2011
FDA approves J&J's Xarelto for stroke prevention

The Food and Drug Administration has approved a drug made by Johnson & Johnson for preventing stroke in patients with abnormal heart rhythm, the agency said.

September 13, 2011
Barry Manilow joins Sanofi's atrial fibrillation education campaign

Singer and atrial fibrillation patient Barry Manilow has joined Sanofi's national education campaign designed to raise awareness about atrial fibrillation.

August 29, 2011
Pfizer, BMS drug more effective than warfarin in AF patients

A drug made by Pfizer and Bristol-Myers Squibb undergoing late-stage clinical trials was more effective than the generic drug warfarin in patients with atrial fibrillation, according to study results released Sunday.

March 15, 2011
Pradaxa added to CVS Caremark's, Medco's commercial preferred drug lists

A drug used to prevent stroke in patients with a form of atrial fibrillation has won preferred Tier 2 formulary status with pharmacy benefit managers Medco Health Solutions and CVS Caremark.

February 14, 2011
Study: Bristol's apixaban effective among atrial fibrillation patients

An investigational drug made by Bristol-Myers Squibb works better than aspirin in reducing the risk of complications in certain patients with heart rhythm problems, according to results of a late-stage clinical trial published in the New England Journal of Medicine.

February 4, 2011
Drug companies move ahead with new medications

The cardiovascular drug market will turn into a difficult conquest in the years to come as it increasingly will be dominated by generics, but that isn’t stopping drug companies from continuing to develop treatments — 299 of them, according to a recent report by the Pharmaceutical Research and Manufacturers of America — for high cholesterol, hypertension, atrial fibrillation, heart failure and other heart-related conditions.

January 3, 2011
Omega-3s may aid gum, heart health

Omega-3 fatty acids from seafood may reduce inflammation and symptoms of gum disease and risk of abnormal heartbeats, according to recent articles in the December 2010 PUFA Newsletter and Fats of Life e-newsletters for health professionals and consumers.

October 19, 2010
FDA approves BI's Pradaxa

The Food and Drug Administration approved a drug for preventing strokes and blood clots in...

September 20, 2010
FDA advisory committee recommends approval of BI's atrial fibrillation drug

A Food and Drug Administration advisory committee has recommended approval of a drug for patients...

May 13, 2010
Brinavess treats atrial fibrillation better than competitor in trial, makers say

An investigational drug for treating a common form of abnormal heart rhythm works better than...

March 17, 2010
Merck, Portola release results of mid-stage betrixaban trial

An investigational pill reduced bleeding in patients with atrial fibrillation better than a widely available...

© 2013 Drug Store News. All Rights Reserved.